MIV Therapeutics Inc (fka MIVI)

[nightwish]

MUST READ: ENTHUSIASTIC VERY LONG-TERM RESULTS OF VESTASYNC TRIAL



VERY LONG-TERM RESULTS (> 2 YEAR) OF THE VESTASYNC I TRIAL WITH A NOVEL, THIRD-GENERATION, HYDROXYAPATITE POLYMER-FREE SIROLIMUS-ELUTING STENT:

http://content.onlinejacc.org/cgi/reprint/55/10_MeetingAbstracts/A179.E1679.pdf

- "This information is current as of September 2, 2010"

- "Conclusion: The novel VES was effective in reducing LL and NIH at 4 and 9 months, with no evidence of late catch-up. Two-year clinical follow-up data showed maintenance of the enthusiastic initial findings.

- "Third year clinical follow-up data will be available at the meeting." (i2 Oral Contributions, Georgia World Congress Center, Room B315, Sunday, March 14, 2010, 4:30 p.m.-4:42 p.m.)


So the third year clinical follow-up data has to be great too if they have chosen to present the data at a congress meeting ...


VERY GOOD TIMES AHEAD FOR MIV THERAPEUTICS IMHO !!!